# Tacrolimus and Daclizumab Versus Tacrolimus and Steroids in Liver Recipients Receiving Sub-optimal Grafts

> **NCT00321074** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 101 (actual)

## Conditions studied

- LIVER TRANSPLANTATION

## Interventions

- **DRUG:** TACROLIMUS

## Key facts

- **NCT ID:** NCT00321074
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2014-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00321074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00321074, "Tacrolimus and Daclizumab Versus Tacrolimus and Steroids in Liver Recipients Receiving Sub-optimal Grafts". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00321074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*